MARKETING ANALYSIS OF ADEMETHIONINE ІN THE PHARMACEUTICAL MARKET OF UKRAINE

Автор(и)

DOI:

https://doi.org/10.30888/2663-5712.2023-18-02-055

Ключові слова:

Ademethionine, hepatoprotector, marketing analysis, assortment

Анотація

The article presents the results of the marketing analysis of Аdemethionine presented on the pharmaceutical market of Ukraine. A review of literature sources on preclinical and clinical studies was conducted, the main areas of application of the drug were

Metrics

Metrics Loading ...

Посилання

Dundar, H. Z., Yilmazlar, T. Management of hepatorenal syndrome. World journal of Nephrology. 2015. №6; 4(2). Р.277-286. doi:10.5527/wjn.v4.i2.277.

Acevedo, J. G., Cramp, M. E. Hepatorenal syndrome: Update on diagnosis and therapy. World journal of Hepatology. 2017. №28; 9(6). Р.293-299. doi: 10.4254/wjh.v9.i6.293.

Radchenko, O.M. Vybir hepatoprotektora dlia likuvannia urazhen pechinky. Health-ua.com Medychna hazeta. 2020. № 1 (470) [Elektronnyi resurs].

Tereshchenko, L.O. Efektyvnist Heptralu u farmakolohichnii korektsii hlutationovoi redoks systemy v selezintsi oprominenykh shchuriv. Aktualni problemy transportnoi medytsyny. 2017. № 2 (48). S. 84−87.

Normatyvno dyrektyvni dokumenty MOZ Ukrainy. Heptral. [Elektronnyi resurs]. Rezhym dostupu: http://mozdocs.kiev.ua/likiview.php?id=12025).

S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis / T. Guo et al. PLoS One. 2015. Vol. 10, № 3. e0122124. doi: 10.1371/journal.pone.0122124.

Lu, Sh. C., Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012. Vol. 92, № 4. P. 1515–1542. doi: 10.1152/physrev.00047.2011.

Cantoni G. L. The nature of the active methyl donor formed enzymatically from l-methionine and adenosine triphosphate.J. Am. Chem. Soc. 1952. Vol. 74, № 11. P. 2942-294. doi: 10.1021/ja01131a519.

«Rokovaia tsepochka» y ademetyonyn / N. B. Huberhryts y dr. Suchasna hastroenterolohiia. 2014. № 4. S. 106–120.

Iurev, K. L. Ademetyonyn pry bolezniakh pecheny. Dokazatelnoe dose. Ukraynskyi medytsynskyi zhurnal. 2011. № 3. S. 63–69.

Tatarenko O. Heptral kak hepatoprotektor vыbora v terapyy patsyentov s zabolevanyiamy pecheny. Hastroэnterolohyia y hepatolohyia: mater. konf. 13 15 maia 2011 h., Ytalyia. Zdorovia Ukrainy. 2011. № 10–15 (268–269). S. 10–12.

S-Adenosylmethionine affects cell cycle pathways and suppresses proliferation in Liver Cells / Yan l. et al. J Cancer. 2019. Vol. 10, № 18. P. 4368–4379. doi: 10.7150/jca.25422.

Ermolova, Yu. V. Heptral pry porazhenyiakh pecheny. Ukrainskyi medychnyi chasopys. 2011. № 4 (84). S. 61–63.

Chernova V. M., Kushnir I. E. Patohenetychni mekhanizmy i terapevtychni aspekty vnutrishnopechinkovoho kholestazu pry khronichnykh zakhvoriuvanniakh pechinky. Suchasna hastroenterolohiia. 2013. № 6 (74). S. 100–107.

Burdak, K. S., Yarnykh T. H., Borshchevska M. I. Hepatoprotektory v likuvanni zakhvoriuvan pechinky: porivnialna kharakterystyka. Suchasni dosiahnennia farmatsevtychnoi tekhnolohii ta biotekhnolohii: zb. nauk. prats za mat. V nauk.-prakt. internet-konf. z mizhn.uchastiu. m. Kharkiv, 18 lyst. 2016 r. Kharkiv, 2016. S. 734–738.

Clinical efficacy of S-adenosylmethionine in patients with non-alcoholic steatohepatitis and chronic kidney disease І-ІІ stage / A. Antoniv et al. Georgian Med News. 2017. Vol. 273. P. 31–36.

S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyl-transferases-1/2 in hepatitis C virus-expressing cells / S. A. Lozano-Sepulveda et al. World J Gastroenterol. 2016. Vol. 22, № 14. P. 3746−3757. doi: 10.3748/wjg.v23.i40.7343

Karas K. N. S-Adenosyl methionine in the therapy of depression and other psychiatric disorders. Drug Dev Res. 2016. Vol. 77, № 7. P. 346−356. doi: 10.1002/ddr.21345.

S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research.; as work group of the american psychiatric association council on research / A. Sharma et al. J Clin Psychiatry. 2017. Vol. 78, № 6. P. 656–667. doi: 10.4088/JCP.16r11113.

Evaluation of antiepileptic effect of S-adenosyl methionine and its role in memory impairment in pentylenetetrazole-induced kindling model in rats / R. M. Dhediya et. al. Epilepsy Behav. 2016. Vol. 61. P. 153–157. doi: 10.1016/j.yebeh.2016.05.024.

Sikora M., Pham K., Ufnal M. Hypotensive effect of S-adenosyl-L-methionine in hypertensive rats is reduced by autonomic ganglia and KATP channel blockers. Amino Acids. 2016. Vol. 48, № 7. P. 1581–1590. doi: 10.1007/s00726-016-2213-4.

S-adenosylmethionine reduces airway inflammation and fibrosis in a murine model of chronic severe asthma via suppression of oxidative stress / S. Y. Yoon et al. Exp Mol Med. 2016. Vol. 48, № 6: e236. doi: 10.1038 / emm.2016.35.

Drachuk V., Zamorskii I., Shchudrova T., Kopchuk T., Goroshko O. Efficacy of ademetionine in acute kidney injury of different genesis. Pharmacology OnLine, 2020;2:92-99. ISSN: 1827-8620

Опубліковано

2023-03-30

Як цитувати

Драчук, В., Заморський, І., Щудрова, Т., Копчук, Т., Горошко, О., & Дикал, М. (2023). MARKETING ANALYSIS OF ADEMETHIONINE ІN THE PHARMACEUTICAL MARKET OF UKRAINE. SWorldJournal, 2(18-02), 18–24. https://doi.org/10.30888/2663-5712.2023-18-02-055

Номер

Розділ

Статті

Статті цього автора (авторів), які найбільше читають